1GLOBAL
22.1.2024 18:18:25 CET | Business Wire | Press release
Kuwait-based low-cost airline Jazeera Airways has partnered with London headquartered Telco 1GLOBAL to become the first airline in the MENA region to launch its own travel eSIM offering. The collaboration will enable Jazeera passengers to communicate cost-effectively and avoid expensive roaming costs when travelling. At the same time, it will serve to strengthen Jazeera Airways´ customer loyalty and satisfaction, while boosting ancillary revenues.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240122511628/en/
Yousef Al Qatami, Chief of Staff at 1GLOBAL. (Source: 1GLOBAL)
Leveraging the power of eSIM
Through the partnership 1GLOBAL will integrate its consumer eSIM technology into Jazeera Airlines' service offering. The process will begin with the implementation of a Jazeera branded QR code and web-based solution, followed by a full-fledged integration into the Jazeera Airways app. The white label solution allows Jazeera to offer eSIM services while maintaining the airlines own look and feel.
Andrew Ward, Vice President Marketing & Customer Experience at Jazeera Airways, says: "We are delighted to be able to offer the 1GLOBAL service to our passengers. We are always looking for ways to reduce travel costs and the 1GLOBAL eSIM offers low call rates for travellers across the Jazeera network."
A benefit for both the airline and its passengers
The roaming solution will be marketed through various communication channels including social media, in-flight magazines, email confirmations and promotional material in airport terminals. The partnership offers benefits for both travellers and Jazeera Airways. By activating the 1GLOBAL roaming eSIM, travellers will be able to stay connected more cost effectively than if they were using their standard roaming plan. They will also have access to high quality 5G & 4G coverage in almost all countries with plenty of flexible tariff options to choose from. Jazeera Airways on the other hand hopes to increase customer loyalty by providing this value-added service. This initiative not only distinguishes Jazeera Airways from its competitors through innovative offerings, but it also aims to increase revenue through ancillary services.
Yousef Al Qatami, Chief of Staff at 1GLOBAL, emphasises: "We are very proud to have supported the Jazeera Airways team in being the first airline in the MENA region to launch an eSIM offering. We are confident in the region's growth trajectory and hope to bring the benefits of eSIM to more local businesses and customers."
About Jazeera Airways
Jazeera Airways operates commercial and cargo flights out of its Jazeera Terminal T5 at Kuwait International Airport. The airline flies to over 64 popular destinations across the Middle East, Central and South Asia, Africa and Europe comprising high-demand business, leisure, religious and weekend destinations.
About 1GLOBAL
Founded in 2022, 1GLOBAL acquired a group of telco assets operational since 2006, including an internationally recognized GSMA-accredited global mobile network. Headquartered in London with our R&D hub in Lisbon, we have grown to over 400 employees across 12 countries and have been granted the status of fully regulated MVNO in 9 of them.
As innovators in eSIM-based GSM mobile services, 1GLOBAL caters to both businesses and individuals with products including mobile call and SMS recording services for businesses, remote SIM provisioning, IOT solutions, Telco-as-a-Service for travel companies, and affordable roaming for everyday consumers.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240122511628/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom